A RETROSPECTIVE STUDY ON THE COMPARISON OF RESPONSIVENESS OF EACH CHEMOTHERAPY FOR RECURRENT OVARIAN CANCER AFTER MAINTENANCE TREATMENT WITH PARP INHIBITORS

Jung Chul Kim*, Junsik Park, Yong Jae Lee, Eunji Nam, Sang Wun Kim, Sung Ho Kim, Young Tae Kim, Jung Yun Lee, Yonsei University College of Medicine, Obstetrics and Gynecology, Seoul, Korea, Republic of; Institute of Women’s Life Medical Science, Yonsei University College of Medicine, Department of Obstetrics and Gynecology, Seoul, Korea, Republic of; Yonsei University College of Medicine, Department of Obstetrics and Gynecology, Women’s Cancer Center, Yonsei University College of Medicine, Seoul, Korea, Republic of; Yonsei Cancer Center, Department of Obstetrics and Gynecology, Seoul, Korea, Republic of

Introduction
In the SOLO2 trial, olaparib demonstrated a significant benefit in disease-free survival in platinum sensitive recurrent ovarian cancer patients with BRCA1/2 mutations, so importance and utility of poly (adenosine diphosphate-ribose) polymerase inhibitors (PARPi) in therapy is gradually increasing. However, there is no medical agreement for treatment after recurrence in ovarian cancer patients who have been administered PARPi, so they are generally treated with platinum-based chemotherapy that have been used previously, or undergo surgery and radiation therapy. Therefore, this study was conducted to confirm the efficacy of each chemotherapy for recurrent ovarian cancer after using PARPi.

Methods
This retrospective study collected the data on recurrent ovarian cancer patients who have used PARPi after platinum-based chemotherapy in front-line to forth-line and using next chemotherapy of Liposomal doxorubicin (PLD)+Carboplatin, Belotecan+Cisplatin and Gemcitabin+Carboplatin from January 01, 2012 to April 30, 2023. The primary end-point was progression free survival (PFS) from the date of disease progression after using PARPi to the date of next disease progression after using those chemotherapy methods.

Results
There was a significant different PFS (p value = 0.0367) in the three groups. And overall, the Gemcitabin +Carboplatin group showed better results than the other two groups, in particular, a significant difference with the PLD+Carboplatin group (p value = 0.0060, Hazard ratio: 2.964, 95% CI 1.128–7.791).

Conclusion/Implications
In the treatment of recurrent ovarian cancer using platinum-based chemotherapy and PARPi,
Gemcitabin + Carboplatin chemotherapy may show slightly better results than other chemotherapies, so additional research on this seems necessary.

**Introduction** CLDN6 is highly expressed in multiple cancers with little to no expression in normal tissues, thus is an ideal target to explore a novel therapeutic. TORKL1–23 is first-in-class ADC targeting the tumor-specific antigen CLDN6.

**Methods** A first in human, 2-part study (TORKL123–001 [NCT05103683]) is characterizing the safety, tolerability, pharmacokinetics (PK), maximum tolerated dose (MTD), and anti-tumor activity of TORKL1–23 monotherapy in participants with ovarian and other advanced solid tumors. Dose escalation (Part 1) implemented an accelerated titration design with up to 6 participants per dose level cohort. Dose expansion (Part 2) will assess participant cohorts with CLDN6-expressing tumors including gynecologic cancers using a CLDN6 IHC companion diagnostic.

**Results** 19 patients with platinum-resistant/refractory ovarian cancer were evaluated across 8 dose levels (0.2 to 2.4 mg/kg IV every 3 weeks, 21 day cycles) (data cutoff 01APR2023). Most pts had ≥ 3 prior treatment lines in the metastatic setting. The most common treatment-related adverse events were Gr1 peripheral neuropathy (n=3), Gr1/2 fatigue (n=2), and Gr1 nausea (n=2). Dose-limiting toxicities have not been observed. PK data show sustained exposure over the dosing interval. Partial responses (PR) were reported in 6/18 efficacy evaluable participants with CLDN6+ ovarian cancer across all dose levels. 3 of 4 participants with ovarian cancer responded at the 2.4 mg/kg dose level.

**Conclusion/Implications** In participants with heavily-pretreated CLDN6-expressing ovarian cancer, the novel TORKL1–23 ADC shows a favorable safety/tolerability profile and encouraging antitumor activity. Dose finding is ongoing to identify optimal doses for subsequent development.